Nucleic Acid Nanoparticles for Treating Human Diseases
Copernicus Therapeutics, Inc., a privately held biotechnology
company, is advancing novel targeting and delivery systems with
broad applications in human therapeutics. Copernicus’ technologies
include a targeting platform enabling the efficient uptake of drugs by
specific cells and tissues and a multi-component delivery platform
that can be applied to nucleic acids to develop therapies for a variety
of human diseases as well as to enhance transgene expression.
Its products are used to treat cystic fibrosis, retinitis pigmentosa,
macular degeneration, diabetic retinopathy and Parkinson’s diseases.
The Company’s targeting, delivery and expression platforms are
complementary and can be combined to enhance the efficacy and
safety of existing drugs, to create novel therapeutics, and to speed
up the drug discovery process.
Copernicus Therapeutics, Inc. was formerly known as Copernicus
Gene Systems, Inc. and was founded in 1995 in Cleveland, Ohio.
The company changed its name to Copernicus Therapeutics, Inc.